基因代理抗血小板药物靶点扰动与动脉瘤性蛛网膜下腔出血风险的孟德尔随机化分析
采用两样本孟德尔随机化分析,评估基因代理的抗血小板药物靶点扰动与动脉瘤性蛛网膜下腔出血(aSAH)及未破裂颅内动脉瘤(uIA)的因果关系。血小板反应性与aSAH风险呈负相关(OR 0.883,95%CI 0.833-0.936,P=2.67E-05),但多数抗血小板药物靶基因对aSAH和uIA未见因果效应;血小板内皮聚集受体1基因表达升高与aSAH风险负相关。结论认为抗血小板药物未被识别为aSAH或uIA的风险或保护因素,靶向血小板内皮聚集受体1可能降低血小板反应性并增加aSAH风险,需进一步研究。
要点
- 血小板反应性与aSAH风险呈负相关(OR 0.883,95%CI 0.833-0.936,P=2.67E-05)。
- 多数抗血小板药物靶基因对aSAH和uIA未见因果效应。
- 血小板内皮聚集受体1基因表达升高与aSAH风险负相关(β2=-0.125,se=0.030,P=2.67E-05)。
核心结论
- 血小板反应性与aSAH风险呈负相关,但抗血小板药物未被识别为aSAH或uIA的风险或保护因素。
- 靶向血小板内皮聚集受体1可能降低血小板反应性并增加aSAH风险,需进一步研究。
研究设计与样本
- 两样本孟德尔随机化分析,评估基因代理的血小板反应性与aSAH的关联。
- 5种广泛使用的抗血小板药物的治疗性血小板聚集抑制由eqtlGen联盟和Genotype-Tissue Expression项目v8联盟的表达数量性状位点及deCODE数据库的蛋白质数量性状位点代理。
- 因果效应采用基于汇总数据的孟德尔随机化、两样本孟德尔随机化、共定位分析和敏感性分析估计,中介孟德尔随机化分析探索潜在通路。
主要发现
- 血小板反应性与aSAH风险呈负相关,未显示明显异质性或多效性(OR 0.883,95%CI 0.833-0.936,P=2.67E-05)。
- 基于汇总数据的孟德尔随机化、两样本孟德尔随机化和共定位分析显示,多数抗血小板药物靶基因对aSAH和uIA未见因果效应。
- 血小板内皮聚集受体1基因表达升高与血小板反应性升高相关(OR 1.46,β1=0.375,se=0.072,P=1.99E-07),且该升高与aSAH风险呈显著负相关(β2=-0.125,se=0.030,P=2.67E-05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出靶向血小板内皮聚集受体1可能降低血小板反应性并增加aSAH风险,强调需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of antiplatelet drugs (APDs) on the rupture risk of unruptured intracranial aneurysms (uIAs) remains controversial. This study aimed to evaluate the causal effects of APDs on aneurysmal subarachnoid hemorrhage (aSAH) and uIA. METHODS: A two-sample Mendelian randomization (TSMR) analysis examined associations between genetically proxied platelet reactivity and aSAH. The therapeutic inhibition of platelet aggregation by 5 widely used APDs was proxied by expression quantitative trait loci from eqtlGen consortium and Genotype-Tissue Expression project v8 consortium and protein quantitative trait loci from deCODE database. Causal effects were estimated with summary-data-based MR, TSMR, colocalization analysis, and sensitivity analysis. Mediation MR analysis explored potential pathways. RESULTS: The platelet reactivity was inversely associated with the risk of aSAH, exhibiting no discernible heterogeneity or pleiotropic effects (odds ratio, 0.883; 95% confidential interval, 0.833-0.936; P = 2.67E-05). No causal effects on the aSAH and uIA were observed for the majority of APD target genes by summary-data-based MR, TSMR, and colocalization analysis. However, elevated genetic expression of platelet endothelial aggregation receptor 1 was associated with increased platelet reactivity with an odds ratio of 1.46 (β1=0.375, se=0.072; P = 1.99E-07), and this elevation showed significant inverse association with aSAH risks (β2=-0.125, se=0.030; P = 2.67E-05). CONCLUSIONS: The platelet reactivity was inversely associated with aSAH risk. However, APDs were not identified as either risk or protective agents for aSAH or uIA. Targeting platelet endothelial aggregation receptor 1 might reduce platelet reactivity and increase aSAH risk, highlighting the need for further research.
引用
- Fan YX, Yang CB, Song ZH, et al. Genetically Proxied Antiplatelet Drug Target Perturbation and Risk of Aneurysmal Subarachnoid Hemorrhage: A Mendelian Randomization Analysis. World Neurosurg. 2025. PMID: 39956371. doi:10.1016/j.wneu.2025.123794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。